药物使用与焦虑和抑郁中不同的微生物特征相关
本研究基于666份粪便样本,采用16S rRNA基因扩增子测序和浅层鸟枪法测序,探讨焦虑障碍和/或重性抑郁障碍与肠道微生物群的关系,并分析抗抑郁药和/或抗焦虑药使用的影响。结果显示抗抑郁药使用与肠道微生物β多样性显著差异相关,效应量大于神经精神障碍诊断;特定微生物与焦虑障碍和重性抑郁障碍相关;随机森林分类器可从微生物谱预测诊断和用药。
要点
- 抗抑郁药使用与肠道微生物β多样性显著差异相关,效应量大于神经精神障碍诊断。
- 特定微生物与焦虑障碍和重性抑郁障碍相关,提示非药物干预潜力。
- 随机森林分类器可从微生物谱预测神经精神障碍诊断和药物使用。
核心结论
- 药物使用对肠道微生物群有显著影响,抗抑郁药使用与β多样性显著差异相关且效应量大于神经精神障碍诊断。
- 特定微生物与焦虑障碍和重性抑郁障碍相关,随机森林分类器可从微生物谱预测诊断和药物使用。
- 女性效应量大于男性,但两性趋势相似;研究鼓励未来探讨肠道微生物群在神经精神障碍及其与药物治疗交互中的作用。
研究设计与样本
- 研究对来自Tulsa-1000和NeuroMAP CoBRE队列的666份粪便样本DNA进行16S rRNA基因扩增子测序和浅层鸟枪法测序。
- 神经精神障碍依据DSM-IV或V标准定义,包括焦虑障碍和/或重性抑郁障碍;药物使用通过ATC分类系统分类,包括抗抑郁药和/或抗焦虑药。
主要发现
- 抗抑郁药使用与肠道微生物β多样性显著差异相关,效应量大于神经精神障碍诊断。
- 特定微生物与焦虑障碍和重性抑郁障碍相关。
- 随机森林分类器可从微生物谱预测神经精神障碍诊断和药物使用。
- 女性效应量大于男性,但两性趋势相似。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This study investigated the relationship between gut microbiota and neuropsychiatric disorders (NPDs), specifically anxiety disorder (ANXD) and/or major depressive disorder (MDD), as defined by Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV or V criteria. The study also examined the influence of medication use, particularly antidepressants and/or anxiolytics, classified through the Anatomical Therapeutic Chemical (ATC) Classification System, on the gut microbiota. Both 16S rRNA gene amplicon sequencing (16S) and shallow shotgun sequencing (WGS) were performed on DNA extracted from 666 fecal samples from the Tulsa-1000 and Neurocomputational Mechanisms of Affiliation and Personality Study Center for Biomedical Research Excellence (NeuroMAP CoBRE) cohorts. The results highlight the significant influence of medication use; antidepressant use is associated with significant differences in gut microbiota beta diversity and has a larger effect size than NPD diagnosis. Next, specific microbes were associated with ANXD and MDD, highlighting their potential for non-pharmacological intervention. Finally, the study demonstrated the capability of Random Forest classifiers to predict diagnoses of NPD and medication use from microbial profiles, suggesting a promising direction for the use of gut microbiota as biomarkers for NPD. Though the effect sizes were larger in females than males, similar trends emerged for both sexes. These findings encourage future research on the gut microbiota's role in NPD and its interactions with pharmacological treatments.
引用
- Dilmore AH, Kuplicki R, McDonald D, et al. Medication use is associated with distinct microbial features in anxiety and depression. Mol Psychiatry. 2025. PMID: 39794490. doi:10.1038/s41380-024-02857-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。